Smoking and disease severity in rheumatoid arthritis: association with polymorphism at the glutathione S-transferase M1 locus.

Staffordshire Rheumatology Centre, Stoke-on-Trent, UK.
Arthritis & Rheumatology (Impact Factor: 7.87). 04/2002; 46(3):640-6. DOI: 10.1002/art.10174
Source: PubMed

ABSTRACT To determine whether the relationship between smoking and disease severity in women with rheumatoid arthritis (RA) is associated with polymorphism at the glutathione S-transferase (GST) M1 locus.
Genotyping for GSTM1 was carried out using polymerase chain reaction methodology on 164 women with established RA. Smoking history was obtained on each patient. Radiographic damage was measured by the Larsen score, and functional outcome was assessed by the Health Assessment Questionnaire (HAQ). Data were analyzed by multiple regression analyses, with correction for age and disease duration.
Ever having smoked was associated with a worse radiographic and functional outcome than was never having smoked. Both past and current smoking were associated with increased disease severity. Stratification by GSTM1 status revealed that polymorphism at this locus affected the relationship between smoking and disease outcome measures. Patients who lacked the GSTM1 gene and had ever smoked had significantly higher Larsen and HAQ scores than did those who lacked the gene and had never smoked. Radiographic outcome in these patients was worse than that in patients who had the GSTM1 gene and who had smoked. The associations were not affected by correction for socioeconomic status. Rheumatoid factor (RF) production was found to be associated with smoking in only the GSTM1-null patients.
Our data suggest that disease outcome in female RA patients with a history of smoking is significantly worse than in those who have never smoked. Smoking was associated with the most severe disease in patients who carried the GSTM1-null polymorphism. This association may be due in part to a relationship between the GSTM1 polymorphism and RF production in smokers.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective To investigate the initial response to treatment and risk of radiographic disease progression in current smokers (S), ex-smokers (EX), and nonsmokers (NS) in a prospective early arthritis cohort and to analyze the influence of smoking cessation on arthritis outcome. Methods The ESPOIR cohort is a prospective cohort study monitoring clinical, biologic, and radiographic data for patients with inflammatory arthritis lasting 6 weeks to 6 months. We examined the influence of smoking status on disease presentation (baseline characteristics) and therapeutic response at 1 year. Risk of structural progression at 12 months, defined as change in the modified Sharp/van der Heijde score ≥1, was analyzed by multivariate regression adjusted for potential confounders (age, sex, joint erosion at inclusion, educational level, positivity for rheumatoid factor or anti–cyclic citrullinated peptide 2 antibodies, and shared HLA–DRB1 epitope). ResultsA total of 813 patients were included; 641 (79%) fulfilled the 2010 American College of Rheumatology/European League Against Rheumatism (EULAR) criteria for rheumatoid arthritis (RA). At inclusion, 138 (21.5%) were S patients, 168 (26.2%) were EX patients, and 335 (52.3%) were NS patients. Baseline acute-phase indicator values were significantly lower for S patients than EX and NS patients (mean ± SD erythrocyte sedimentation rate was 24.2 ± 18.2 mm/hour versus 33.4 ± 28.0 and 31.4 ± 25.0 [P = 0.02], respectively, and mean ± SD C-reactive protein level was 17.7 ± 28.0 mg/dl versus 28.5 ± 42.5 and 21.4 ± 29.0 [P = 0.01], respectively). Smoking status had no influence on Disease Activity Score in 28 joints, Health Assessment Questionnaire score, EULAR response, or use of disease-modifying antirheumatic drugs and biologic therapy in the first 12 months of followup (P > 0.05). The adjusted risk for structural disease progression was associated with active smokers (odds ratio 0.50 [95% confidence interval 0.27–0.93], P = 0.028). Sixteen patients had stopped smoking at 12 months, with no significant difference in observed outcomes from other patients. Conclusion In this large prospective cohort of patients with early arthritis, smoking status had no significant effect on disease activity and disability but did reduce 1-year radiographic disease progression. The antiinflammatory role of nicotine may explain the lower systemic inflammation and structural disease progression in current smokers with early RA.
    Arthritis Care & Research. 12/2013; 65(12).
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Rheumatoid arthritis (RA), the chronic autoimmune disease with several opinions about its aetiology, has affected more than 50 million people in the world. The aim of this 2008 study was to investigate the association between smoking and RA in Hamedan, a western city of Iran. Methods: As a case-control study, information from 130 cases and 130 controls, matched for age and sex, were collected by questionnaire and analysed using SPSS (chi-square, phi and Cramer tests). Results: From 130 cases, 80 cases were females and the rest were males. Statistical analysis showed that smoking less or more than 10 cigarettes daily has a significant association with RA in both sexes, together or separately (p < .05). However, there is no significant association between duration of smoking cessation within 2 years or more, and RA in both sexes (p > .05). This means that cigarette cessation at any time can be useful in RA prevention. Conclusion: Considering previous global investigations on this topic and the results of our study, it seems that smoking even low numbers of cigarettes affects the presence of RA and it is never too late to give up smoking.
    The Journal of Smoking Cessation 06/2010; 5(1):1-6.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Little is known about the genes regulating disease severity and joint damage in rheumatoid arthritis (RA). In the present study we analyzed the gene expression characteristics of synovial tissues from four different strains congenic for non-MHC loci that develop mild and non-erosive arthritis, compared with severe and erosive DA rats. DA.F344(Cia3d),DA.F344(Cia5a), DA.ACI(Cia10) and DA.ACI(Cia25) rats developed mild arthritis compared with DA. 685 genes had significantly different expression between congenics and DA, independently of the specific congenic interval, suggesting that these genes represent a new non-genetic core group of mediators of arthritis severity. This core group included genes not previously implicated on, or with unclear role in arthritis severity such as Tnn, Clec4m and Spond1 among others increased in DA. The core genes also included Scd1, Selenbp1 and Slc7a10 increased in congenics. Genes implicated in nuclear receptor activity, xenobiotic and lipid metabolism were also increased in the congenics, correlating with protection. Several disease mediators were among the core genes reduced in congenics, including IL-6, IL-17 and Ccl2. Analyses of upstream regulators (genes, pathways or chemicals) suggested reduced activation of Stat3 and TLR-related genes and chemicals in congenics. Additionally, cigarette smoking was among the upstream regulators activated in DA, while p53 was an upstream regulator activated in congenics. Congenic-specific differential expression and detection was observed in each individual strain. In conclusion, this new non-genetically regulated core genes of disease severity or protection in arthritis should provide new insight into critical pathways and potential new environmental risk factor for arthritis.
    Physiological Genomics 11/2013; 45(22):1109-22. · 2.81 Impact Factor

Full-text (2 Sources)

Available from
Oct 15, 2014